trending Market Intelligence /marketintelligence/en/news-insights/trending/wl7x-jnAHMKaTElEn7RlGA2 content esgSubNav
In This List

Mylan receives tentative US approval for generic HIV treatment

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Mylan receives tentative US approval for generic HIV treatment

The U.S Food and Drug Administration granted tentative approval to Mylan NV's generic HIV treatment under the U.S. President's Emergency Plan for AIDS Relief.

The anti-retroviral treatment, known as TDF-3TC-DTG, or TLD, is recommended as the first line of treatment for patients in developing countries. The drug combines the active ingredients from three brand-name medicines: ViiV Healthcare's Tivicay and Epivir, and Gilead Sciences Inc.'s Viread.

The U.S. President's Emergency Plan for AIDS Relief is a U.S. government initiative to address the global HIV/AIDS epidemic, primarily in Africa.

ViiV Healthcare is majority owned by GlaxoSmithKline plc